SEMA6A

Across TCGA pan-cancer cohorts, SEMA6A mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SEMA6A data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SEMA6A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SEMA6A expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC and GBM are the cancer types where SEMA6A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.315	0.720	.012	4	view →
GBM	OS	Quartile	All	0.521	0.367	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SEMA6A–CCRCC (DFS)

Open the CCRCC breakdown →